Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Morales

Optometrist Webster, TX Doctor of Optometry

NPI 1376546796 CMS profile 829239

905 W Medical Center Blvd Ste 101, Webster, TX 77598

Open in the dashboard

General payments

$5,260

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Morales of Webster, TX is reported in the CMS Open Payments database as having received $5,260 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $316 12
2024 General $374 9
2023 General $1,152 37
2022 General $1,378 29
2021 General $579 11
2019 General $1,461 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Morales
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Mary Morales were reported at $316. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Mary Morales Optometrist median Middle half National median
2019 $1,461 $159 $67–$371 $163
2020 $0 $72 $29–$165 $114
2021 $579 $125 $46–$292 $132
2022 $1,378 $162 $66–$374 $149
2023 $1,152 $177 $72–$406 $160
2024 $374 $188 $77–$427 $164
2025 $316 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Vision Care, Inc. $1,643 47 payments
  2. Alcon Vision LLC $1,444 18 payments
  3. CooperVision Inc. $255 7 payments
  4. AbbVie, Inc. $234 5 payments
  5. Glaukos Corporation $233 2 payments
  6. RxSight Inc $219 4 payments
  7. Visioneering Technologies, Inc. $196 1 payment
  8. Synergeyes, Inc. $188 3 payments
  9. Kala Pharmaceuticals, Inc. $180 6 payments
  10. Dompe US, Inc. $123 2 payments
  11. Other $546 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,568 104 payments
  2. Travel and Lodging $667 3 payments
  3. Honoraria $26 1 payment
Products named General payments · program years 2019–2025
  1. Acuvue $1,558 43 payments
  2. DAILIES $1,084 6 payments
  3. VUITY $234 5 payments
  4. KXL System $233 2 payments
  5. Photrexa $233 2 payments
  6. Duette Contact Lenses $188 3 payments
  7. EYSUVIS $180 6 payments
  8. TOTAL30 $150 4 payments
  9. LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) $127 1 payment
  10. MyDay Contact Lens $124 2 payments
  11. Other $2,067 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record